Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

$MBRX News – Moleculin Announces Reminder for Conference Call to Discuss Positive Developments Regarding Annamycin

Thursday, October 20, 2016 5:59
% of readers think this story is Fact. Add your two cents.

(Before It's News)

FinancialNewsMedia.com News Alert: Call Scheduled for Today to Include General Corporate Update – HOUSTON, TX — (http://www.financialnewsmedia.com News Alert) – Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced a reminder that it will host a conference call to discuss important positive developments regarding Annamycin, its drug candidate for the treatment of Acute Myeloid Leukemia, as well as to provide a general corporate update. (Read this and more details about Moleculin at http://financialnewsmedia.com/profiles/mbrx.html)

The call will be held today, October 20, 2016 at 5:00 pm Eastern Time and can be accessed with the following dial-in information:

Participant dial in (toll free): 1-877-418-3859 – Participant international dial in: 1-412-902-6506 – Please ask to be joined into the Moleculin call. – Participant Entry Number: 4494430

This conference call will be recorded and made available for replay as follows: US Toll Free: 1-877-344-7529 – International Toll: 1-412-317-0088 – Canada Toll Free:1-855-669-9658 – Replay Access Code: 10095171 – End Date: November 3, 2016

To access the replay using an international dial-in number, please select the link below: https://services.choruscall.com/ccforms/replay.html

About Moleculin Biotech, Inc. – Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. The other portfolio…

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.